Table 2. Efficacy (N=47).

Study Arm	NE patients N	PD patients N [%]	SD patients N [%]	Total patients (N)	Median PFS in months	95% CI
Arm A	5	8	10	23	3.36	1.41–5.66
Arm B	6	8	10	24	3.50	1.64–4.47
Total patients	11	16 [44]	20 [55]	47	–	–

NE, not evaluable; PD, progressive disease; SD, stable disease; PFS, progression free survival.